Engineering toxin-resistant therapeutic stem cells to treat brain tumors

Stem Cells

Volumn 33, Issue 2, 2015, Pages 589-600

  Stuckey, Daniel W ^a,b   Hingtgen, Shawn D ^a,b   Karakas, Nihal ^a,b   Rich, Benjamin E ^c   Shah, Khalid ^a,b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Cytotoxin; Glioblastoma; Molecular imaging; Stem cell; Targeted therapy

Indexed keywords

CYTOTOXIN; ELONGATION FACTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA2; PSEUDOMONAS EXOTOXIN; RECOMBINANT INTERLEUKIN 13; BACTERIAL PROTEIN; EXOTOXIN; HYBRID PROTEIN; INTERLEUKIN 13;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABILITY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL ENCAPSULATION; CELL ENGINEERING; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INFUSION; DRUG POTENTIATION; DRUG RELEASE; EXTRACELLULAR MATRIX; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; LONG TERM SURVIVAL; MOUSE; MULTIMODAL IMAGING; NEURAL STEM CELL; NONHUMAN; PROTEIN ENGINEERING; PROTEIN SYNTHESIS INHIBITION; TARGET CELL; ANIMAL; BRAIN NEOPLASMS; CELL LINE; DRUG RESISTANCE; GENETIC ENGINEERING; GENETICS; METABOLISM; PATHOLOGY; PSEUDOMONAS; SECRETION (PROCESS); STEM CELL; STEM CELL TRANSPLANTATION; XENOGRAFT;

MUS; PSEUDOMONAS EXOTOXIN;

ANIMALS; BACTERIAL PROTEINS; BRAIN NEOPLASMS; CELL LINE; DRUG RESISTANCE; EXOTOXINS; GENETIC ENGINEERING; HETEROGRAFTS; HUMANS; INTERLEUKIN-13; MICE; PEPTIDE ELONGATION FACTOR 2; PSEUDOMONAS; RECOMBINANT FUSION PROTEINS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84921677677     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1874     Document Type: Article

References (55)

1. Hwang J, Fitzgerald DJ, Adhya S, et al. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 1987; 48: 129.
2. Weldon JE, Pastan I,. A guide to taming a toxin-Recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011; 278: 4683.
3. Okada H, Low KL, Kohanbash G, et al. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol 2008; 88: 245.
4. Wykosky J, Gibo DM, Stanton C, et al. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 2008; 14: 199.
5. Jarboe JS, Johnson KR, Choi Y, et al. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: Implications for targeted therapies. Cancer Res 2007; 67: 7983.
6. Debinski W, Slagle B, Gibo DM, et al. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol 2000; 48: 103.
7. Candolfi M, Xiong W, Yagiz K, et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci USA 2010; 107: 20021.
8. Debinski W, Gibo DM,. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 2000; 6: 440.
9. Liu H, Jacobs BS, Liu J, et al. Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: Non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother 2000; 49: 319.
10. Theuer CP, FitzGerald D, Pastan I,. A recombinant form of Pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing. J Biol Chem 1992; 267: 16872.
11. Lorimer IA, Keppler-Hafkemeyer A, Beers RA, et al. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 1996; 93: 14815.
12. Liu TF, Willingham MC, Tatter SB, et al. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem 2003; 14: 1107.
13. Ciardiello F, Tortora G,. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160.
14. Kreitman RJ, Pastan I,. Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 2006; 7: 1301.
15. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999; 94: 3340.
16. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622.
17. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23: 6719.
18. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009; 27: 2983.
19. Debinski W, Obiri NI, Pastan I, et al. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995; 270: 16775.
20. Debinski W, Obiri NI, Powers SK, et al. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1995; 1: 1253.
21. Husain SR, Joshi BH, Puri RK,. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001; 92: 168.
22. Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 2010; 12: 871.
23. Wang Y, Jiang T,. Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management. Cancer Lett 2013; 331: 139.
24. Huang PH, Xu AM, White FM,. Oncogenic EGFR signaling networks in glioma. Sci Signal 2009; 2: re6.
25. Holliger P, Hudson PJ,. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126.
26. van de Water JA, Bagci-Onder T, Agarwal AS et al. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proc Natl Acad Sci USA 2012; 109: 16642.
27. Roovers RC, Laeremans T, Huang L, et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother 2007; 56: 303.
28. Kauer TM, Figueiredo JL, Hingtgen S, et al. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci 2012; 15: 197.
29. Shah K, Hingtgen S, Kasmieh R, et al. Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model. J Neurosci 2008; 28: 4406.
30. Kock N, Kasmieh R, Weissleder R, et al. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 2007; 9: 435.
31. Sasportas LS, Kasmieh R, Wakimoto H et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009; 106: 4822.
32. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009; 69: 3472.
33. Bagci-Onder T, Wakimoto H, Anderegg M, et al. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 2011; 71: 154.
34. Shulga-Morskoy S, Rich BE,. Bioactive IL7-diphtheria fusion toxin secreted by mammalian cells. Protein Eng Des Sel 2005; 18: 25.
35. Haq R, Yokoyama S, Hawryluk EB, et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA 2013; 110: 4321.
36. Gazdar AF, Kurvari V, Virmani A, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 1998; 78: 766.
37. Lasfargues EY, Coutinho WG, Redfield ES,. Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst 1978; 61: 967.
38. Villa A, Snyder EY, Vescovi A, et al. Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS. Exp Neurol 2000; 161: 67.
39. Kohno K, Uchida T,. Highly frequent single amino acid substitution in mammalian elongation factor 2 (EF-2) results in expression of resistance to EF-2-ADP-ribosylating toxins. J Biol Chem 1987; 262: 12298.
40. Wu AH, Low WC,. Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter. Neuro Oncol 2003; 5: 179.
41. Gill DM, Pappenheimer AM, Jr.; Brown R, et al. Studies on the mode of action of diphtheria toxin. VII. Toxin-stimulated hydrolysis of nicotinamide adenine dinucleotide in mammalian cell extracts. J Exp Med 1969; 129: 1.
42. Iglewski BH, Kabat D,. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc Natl Acad Sci USA 1975; 72: 2284.
43. Yamaizumi M, Mekada E, Uchida T, et al. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978; 15: 245.
44. Corsten MF, Shah K,. Therapeutic stem-cells for cancer treatment: Hopes and hurdles in tactical warfare. Lancet Oncol 2008; 9: 376.
45. Ahmed AU, Alexiades NG, Lesniak MS,. The use of neural stem cells in cancer gene therapy: Predicting the path to the clinic. Curr Opin Mol Ther 2010; 12: 546.
46. Aboody KS, Najbauer J, Danks MK,. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008; 15: 739.
47. Stuckey DW, Shah K,. Stem cell-based therapies for cancer treatment: separating hope from hype. Nature Reviews Cancer 2014; 14: 683.
48. Foley BT, Moehring JM, Moehring TJ,. Mutations in the elongation factor 2 gene which confer resistance to diphtheria toxin and Pseudomonas exotoxin A. Genetic and biochemical analyses. J Biol Chem 1995; 270: 23218.
49. Asthagiri AR, Pouratian N, Sherman J, et al. Advances in brain tumor surgery. Neurol Clin 2007; 25: 975.
50. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190.
51. Altaner C, Altanerova V, Cihova M, et al. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. Int J Cancer 2014; 134: 1458.
52. Bello L, Giussani C, Carrabba G, et al. Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. Clin Cancer Res 2002; 8: 3539.
53. Herbst RS,. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59: 21.
54. Jacobs VL, Valdes PA, Hickey WF, et al. Current review of in vivo GBM rodent models: Emphasis on the CNS-1 tumour model. ASN Neuro 2011; 3: e00063.
55. Fujisawa T, Joshi BH, Puri RK,. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer. J Transl Med 2011; 9: 37.